echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Newland green, the recombiner of Zesheng pharmaceutical, is expected to be approved for listing in China

    Newland green, the recombiner of Zesheng pharmaceutical, is expected to be approved for listing in China

    • Last Update: 2020-01-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020 / 01 / 19) complete elimination of liquid tumor in mice Harvard scientists invented magic solid vaccine; Zesheng pharmaceutical recombinant human Newland green is expected to be approved for listing in China; Ma Yinglong's "erythromycin ointment" and sunflower pharmaceutical's "Yinqiao cold capsule" are not qualified; whether 17 new cases of pneumonia in Wuhan in one day have not been detected in other cities in the Mainland Roche is powerful Because the new drug was approved If it's unqualified, check it carefully! Take protective measures.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.